toxomiR®
microRNA biomarkers of toxicity
As toxicity poses substantial risks across pharmaceuticals and environmental exposures, searching for novel biomarkers is paramount for enhancing safety evaluations, drug development, and environmental monitoring. toxomiR® refers to a subset of tissue- and cell-type specific microRNAs in the liver, kidney, central nervous system, heart, muscle, lung, pancreas, and vasculature. toxomiRs® can be measured in liquid biopsies such as serum, plasma, and urine obtained from clinical and non-clinical studies and inform about organ injury. The magnitude of change in toxomiR levels was shown to be associated with the extent of histopathological tissue damage.
This recently published review gives detailed insight into the clinical utility of circulating microRNAs as toxicity biomarkers.
benefits
The toxomiR® panel is available as an in-house service from TAmiRNA. Customers can select between the full toxomiR® panel covering 8 organ systems or customized panels for selected organs.
Non-invasive screening of toxic effects using serum, plasma, or urine.
High sequence conservation of microRNA biomarkers enables rapid cross-species translation from pre-clinical to clinical studies.
toxomiRs are sensitive and specific biomarkers suitable for diagnosing tissue damage in the liver, pancreas, heart, skeletal muscle, vasculature, kidney, lung, and brain.
Rapid and robust solution for quantifying toxic effects in human plasma samples
Customized service available with analysis targeted on specific set of microRNAs or tissue types
service requirements
- Frozen serum, plasma, or urine samples.
- 25 – 200 µl input volume required.
- the toxomiR biomarker panel is highly conserved, supporting the analysis of human, mouse, rat, dog, pig, and NHP samples.
intended use
toxomiRs® can be used in pre-clinical and clinical phases of drug safety assessment. The microRNAs panel enable early and reliable detection as well as monitoring of adverse events.
The toxomiR® panel can be used:
- To understand toxic mechanisms in liver, kidney, central nervous system, heart, muscle, lung, pancreas, vascular injury, and due to endocrine disruption
- For identifying and monitoring safety risks in drug development
- For early detection of tissue injury
service description
- The toxomiR® panel is only available as in-house service
- 200 µL serum and plasma are recommended (lower volumes can be used but require pre-testing)
- Deep-frozen (-70°C or lower) serum and plasma samples can be used
- 19 toxomiRs® and 5 quality controls are measured per sample
- Ready-to-use data for presentation and publication will be provided
dataset
the toxomiR® service include:
- Standardized analysis of qPCR data
- Quality control: inspect amplification curves, melting temperature, spike-in and hemolysis controls
- Ready-to-use data for presentation and publication will be provided
- Post project consultations to discuss next steps are included
- Customization is possible: upon request the analysis can be targeted to a specific set of microRNAs/tissue
price list
| sample number | price/sample |
|---|---|
| n<=48 | € 275.– |
| n<=96 | € 194.– |
| n<=154 | € 175.– |
| n<=192 | € 156.– |
| n>192 | € 147.– |
frequently asked questions (FAQ)
